Bank of America Securities Remains Bullish on Amicus Therapeutics (FOLD) With a $13 PT

Amicus Therapeutics, Inc. (NASDAQ:FOLD) is one of the best strong buy stocks to buy under $10. In a report released on July 15, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on Amicus Therapeutics, Inc. (NASDAQ:FOLD) with a price target of $13.00.

Is Amicus Therapeutics, Inc. (FOLD) the Best Low Cost Stock to Buy According to Billionaires?

Doctors in a lab coat attending to a patient receiving enzyme replacement therapies.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) reported $125.2 million in total revenues for fiscal Q1 2025, representing a 15% operational growth measured at constant exchange rates (CER) and a currency headwind of $1.4 million or 1%.

The company has cash, cash equivalents, and marketable securities totaling $250.6 million as of March 31, 2025, reflecting minute growth as compared to $249.9 million at December 31, 2024.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) is a biotech company that discovers, develops, and delivers medicines to treat metabolic diseases. Its product portfolio includes the first and only approved oral precision medicine to treat Fabry disease, a clinical-stage treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.